Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the treatment you received is working as intended.

KEY POINTS:

• Stable disease: Your liver metastases (cancer spread to the liver) show "similar distribution and intensity" compared to your June scan, meaning they haven't grown or shrunk significantly
• Measurable shrinkage in some lesions: Several liver tumors actually got slightly smaller (e.g., one went from 0.9 x 1.2 cm to 0.6 x 1.0 cm), which is a positive sign
• No new tumors: The report explicitly states "no new Dotatate-avid liver lesion" and "no findings suggestive of new metastatic disease"
• Bone findings are stable: Your single femur (thighbone) lesion remains unchanged, and new uptake in your spine appears to be degenerative/inflammatory, not cancer
• Lymph nodes unchanged: Nodes in your neck and chest show no significant growth

NEXT STEP: Schedule a follow-up appointment with your oncologist to discuss whether to continue, adjust, or complete your current trial treatment based on these stable results.

---

FULL ANSWER

Understanding Your PET Scan Results

You've completed a phase 1b trial with VMT-α-NET (a targeted therapy for neuroendocrine tumors), and your follow-up Gallium-68 DOTATATE PET/CT scan shows stable disease—which is an excellent outcome in cancer treatment. Let me walk you through what this means in the context of your specific situation.

Your Cancer Background (Context)

According to your scan report, you have:

• Primary tumor: Pancreatic neuroendocrine tumor (NET), grade 2, well-differentiated, with a Ki-67 index of 2-5% (a measure of how fast cells are dividing—lower is better)
• Metastatic disease: Cancer has spread to your liver (multiple lesions), one bone lesion in your right femur, and some lymph nodes
• Prior treatments:
  • Distal pancreatectomy and splenectomy (surgery to remove part of pancreas and spleen) in March 2024
  • Lanreotide (a somatostatin analog that slows tumor growth) started May 2024
  • Hepatic artery embolization (blocking blood flow to tumors) in December 2024 and January 2025
  • VMT-α-NET trial treatment (your current experimental therapy)

---

What "Stable Disease" Means

Stable disease is one of the best outcomes you can have on a cancer treatment, especially in a phase 1b trial. According to NCCN Guidelines for neuroendocrine tumors, response assessment uses specific criteria to evaluate whether tumors are shrinking (response), staying the same (stable), or growing (progression). Your scan shows:

1. Liver Metastases: Stable with Some Shrinkage

Your report states: "Overall similar distribution and intensity of numerous foci of markedly somatostatin receptor expressing liver metastases, suggesting stable disease burden."

What this means:

• Your liver tumors are showing marked uptake of the DOTATATE tracer, which means they're actively expressing somatostatin receptors—exactly what your treatment targets
• The distribution (where they are) and intensity (how much tracer they're taking up) are similar to your [date removed] scan
• However, several individual lesions actually got slightly smaller:
  • Segment 7 lesion: decreased from 0.6 x 0.8 cm to 0.5 x 0.7 cm
  • Segment 4 lesion: decreased from 0.9 x 1.2 cm to 0.6 x 1.0 cm
  • Segment 2 lesion: previously 0.6 x 0.7 cm (not clearly visible on current CT, but stable)

These small decreases in size suggest your treatment is having a positive effect, even if the overall burden hasn't dramatically changed.

2. No New Liver Lesions

The report explicitly states: "No new Dotatate-avid liver lesion."

This is critical—it means your cancer hasn't spread to new areas of your liver, which would indicate progression.

3. Bone Disease: Stable

Your single osseous (bone) metastasis in the right femur shows "similar mild uptake" compared to your previous scan. This means:

• No growth of this lesion
• No new bone metastases elsewhere

The new faint uptake in your L3 and L4 vertebrae is noted as "most likely inflammatory/degenerative changes"—meaning these are likely age-related wear-and-tear changes, not cancer.

4. Lymph Nodes: Stable and Non-Enlarged

Your neck and chest lymph nodes show:

• "Overall similar size and no significant change in mild Dotatate uptake"
• Nodes remain non-enlarged
• Examples: left submandibular node stable at 12 x 87 mm (unchanged from prior)

This is important because growing lymph nodes would suggest disease progression.

5. No New Metastatic Disease

The report concludes: "No findings suggestive of new metastatic disease."

This means your cancer hasn't spread to new organs (lungs, brain, other sites).

---

What This Means for Your Treatment

According to NCCN Guidelines for neuroendocrine tumors, stable disease on imaging typically indicates:

1. Your current treatment is working: The VMT-α-NET trial therapy, combined with your ongoing lanreotide and prior embolization, is controlling your disease
2. No immediate progression: You're not in a situation where urgent treatment changes are needed
3. Continued monitoring is appropriate: Your oncologist will likely recommend continuing your current approach with regular imaging follow-up

The NCCN Guidelines emphasize that for patients with metastatic NETs, the goal is to slow or stop disease progression, manage symptoms, and maintain quality of life. Stable disease achieves these goals.

---

Important Context About Your Scan Type

Your scan used Gallium-68 DOTATATE PET/CT, which is the gold standard for imaging neuroendocrine tumors. According to NCCN Guidelines for neuroendocrine tumors:

• DOTATATE PET is preferred for detecting somatostatin receptor-positive NETs (which yours is)
• The uptake intensity scale used in your report (no uptake → mild → moderate → marked) helps doctors assess how "active" each tumor is
• Your tumors show marked uptake, confirming they're expressing the somatostatin receptors that your treatments target

---

Questions to Ask Your Oncologist at Your Next Visit

Based on these stable results, here are specific questions to help guide your next treatment decisions:

1. "Based on these stable results, do you recommend I continue the VMT-α-NET trial, or should we consider adjusting my treatment?"

   • This helps clarify whether your oncologist sees benefit in continuing the current approach

2. "The report shows some lesions got slightly smaller. Does this suggest the trial drug is working, or is this within normal measurement variation?"

   • This helps you understand whether shrinkage is meaningful or just normal scan-to-scan variation

3. "How often should I have follow-up PET scans to monitor for any changes?"

   • Typical surveillance intervals for stable NETs are every 3-6 months, but your oncologist may recommend a different schedule

4. "Are there any new treatment options I should know about if my disease progresses in the future?"

   • This helps you stay informed about your options (e.g., additional targeted therapies, chemotherapy, or other clinical trials)

5. "What symptoms or changes should I report to you immediately rather than waiting for my next scan?"

   • This ensures you know when to seek urgent care

---

What "Stable" Means in the Bigger Picture

In cancer treatment, especially for advanced neuroendocrine tumors, stable disease is often considered a success. Here's why:

• Grade 2 NETs are slower-growing than higher-grade cancers, but they can still progress
• Stable disease buys time: It means your treatment is controlling the cancer while you maintain quality of life
• It's better than progression: Progressive disease would require changing your treatment strategy
• It's realistic: Complete remission (disappearance of all cancer) is less common with metastatic NETs, so stable disease is often the goal

According to the NCCN Guidelines and the American Cancer Society, for patients with metastatic NETs, the focus shifts from cure to:

• Controlling disease progression
• Managing symptoms (especially hormonal symptoms like flushing or diarrhea if present)
• Maintaining quality of life
• Monitoring for changes that might require treatment adjustment

---

Important Reminder About Your Specific Situation

Your oncologist has access to:

• Your complete medical history and prior imaging
• Your specific trial protocol and treatment schedule
• Your symptoms and how you're tolerating treatment
• Your overall health status and other medical conditions

This scan interpretation is educational and helps you understand your results. Your oncologist will determine the most appropriate next steps for YOUR specific case based on all this information combined.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.